ImmunoVax

Version française

Design: Observational and longitudinal study
Status: Recruitment completed - Study in progress
Study duration per participant: 12 – 18 month

Study Title: « Evaluation of the Induction of Protective Immune Responses by Vaccination against SARS-CoV-2 in Immunocompromised Patients. »

This research consists of evaluating and monitoring the induction and durability of protective immune responses induced by vaccination against SARS-COV-2 in vulnerable populations. At least 700 patients with cancer, onco-hematological disease, benign hematological disease, primary immunodeficiency, systemic inflammatory disease, or organ transplantation at the University Hospital of Lausanne (CHUV) are invited to enroll in the study prior to their first vaccination dose.

Blood samples are collected repeatedly over 18 months.  Clinical information, including safety variables related to vaccine adverse events and clinical variables assessing symptoms related to possible SARS-CoV-2 infection, is collected at each post-vaccination visit.